Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.

Expert opinion on investigational drugs - 1 Sept 2013

Shah Nihar, Pierce Tracey, Kowdley Kris V

Abstract excerpt

INTRODUCTION: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have dramatically altered the treatment landscape for this chronic disease. In 2011, the protease inhibitors (PIs) boceprevir and telaprevir in combination with peginterferon (peg-IFN) and ribavirin (RBV) were the first direct-acting antivirals (DAAs) approved in the United States for treatment of genotype (GT) 1 HCV. Several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Clinical Trials as Topic
Share to Drug Approval

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to United States

Source

Identifiers

PMID: 23735127
DOI: 10.1517/13543784.2013.806482

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.PMID 23735127Read ↗

Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

The hepatitis C revolution part 1: antiviral treatment options.Semantic proximity Read ↗

Direct-acting antivirals: the endgame for hepatitis C?Semantic proximity Read ↗

[Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].Semantic proximity Read ↗

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.Semantic proximity Read ↗

Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.Semantic proximity Read ↗

Advances in hepatitis C therapies.Semantic proximity Read ↗

Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Semantic proximity Read ↗

Direct-Acting Antiviral Therapy for Treatment of Acute and Recent Hepatitis C Virus Infection: A Narrative Review.Semantic proximity Read ↗

Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Semantic proximity Read ↗

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.